Literature DB >> 9555114

P53 expression in stage I squamous cell lung cancer.

J Moldvay1, J Strausz, M Egerváry, L Agócs, J Bocsi, Z Schaff.   

Abstract

P53 expression was studied using immunohistochemistry in patients (n=94) with pathologic stage I squamous cell lung cancer treated surgically between 1991-1992. The overall p53 positivity ratio was 48/94. 83 of the cases proved to be suitable for follow-up analysis carried out in November, 1995. 46/83 were p53 positive, and 25/46 patients were alive at the time of analysis. The patients who died (21/46) had a mean survival time of 17.5 months. In p53 negative cases (37/83), however, 29/37 patients were still alive at the time of follow-up, and 8/37 had died with a mean survival time of 23.1 months. A significant correlation could be found between p53 immunopositivity and reduced survival time (p=0.0125). Interestingly, out of 83 cases analyzed histologic evidence of tuberculous scar tissue was present in 9 tumors with a p53 positivity ratio of only 1/9. When flow cytometry was used to examine tumor samples from all subgroups mentioned above (n=32), no correlation was found between the p53 immunopositivity or the prognosis and the DNA content of tumor tissues. Our results suggest that in the early stage of squamous cell lung cancer the p53 positivity may be an indicator of a more aggressive tumor behavior and a shortened survival time.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9555114     DOI: 10.1007/BF02904688

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  51 in total

Review 1.  Nuclear p53 overexpression is an independent prognostic parameter in node-negative non-small cell lung carcinoma.

Authors:  P Dalquen; G Sauter; J Torhorst; E Schultheiss; P Jordan; S Lehmann; M Solèr; P Stulz; M J Mihatsch; F Gudat
Journal:  J Pathol       Date:  1996-01       Impact factor: 7.996

2.  [Respective roles of the products of the mdr1 and p53 genes in drug resistance of bronchial cancers].

Authors:  M Peoc'h; E Brambilla; D Moro; S Gazzeri; C Brambilla
Journal:  Bull Cancer       Date:  1994-12       Impact factor: 1.276

3.  Comparative analysis of p53 gene mutations and protein accumulation in human non-small-cell lung cancer.

Authors:  B Top; W J Mooi; S G Klaver; L Boerrigter; P Wisman; H R Elbers; S Visser; S Rodenhuis
Journal:  Int J Cancer       Date:  1995-04-21       Impact factor: 7.396

Review 4.  Molecular events in lung cancer.

Authors:  J A Roth
Journal:  Lung Cancer       Date:  1995-06       Impact factor: 5.705

5.  Mutations of the p53 gene in male breast cancer.

Authors:  A Anelli; T F Anelli; B Youngson; P P Rosen; P I Borgen
Journal:  Cancer       Date:  1995-05-01       Impact factor: 6.860

6.  Clinicopathological study of primary malignant tumors of the lung: an analysis of 993 tumors resected at the Kanazawa University Hospital between 1979-1993.

Authors:  A Nonomura; Y Mizukami; J Shimizu; M Oda; S Murakami; Y Watanabe; T Kobayashi; R Kamimura; T Takashima; M Kitagawa
Journal:  J Surg Oncol       Date:  1995-01       Impact factor: 3.454

7.  Aberrant p53 expression predicts clinical resistance to cisplatin-based chemotherapy in locally advanced non-small cell lung cancer.

Authors:  V Rusch; D Klimstra; E Venkatraman; J Oliver; N Martini; R Gralla; M Kris; E Dmitrovsky
Journal:  Cancer Res       Date:  1995-11-01       Impact factor: 12.701

8.  Aberrant expression of p53 or the epidermal growth factor receptor is frequent in early bronchial neoplasia and coexpression precedes squamous cell carcinoma development.

Authors:  V Rusch; D Klimstra; I Linkov; E Dmitrovsky
Journal:  Cancer Res       Date:  1995-03-15       Impact factor: 12.701

9.  p53 antibodies in the sera of lung cancer patients: comparison with p53 mutation in the tumour tissue.

Authors:  C P Wild; M Ridanpää; S Anttila; R Lubin; T Soussi; K Husgafvel-Pursiainen; H Vainio
Journal:  Int J Cancer       Date:  1995-06-22       Impact factor: 7.396

10.  p53 expression in normal and dysplastic bronchial epithelium and in lung carcinomas.

Authors:  C Walker; L J Robertson; M W Myskow; N Pendleton; G R Dixon
Journal:  Br J Cancer       Date:  1994-08       Impact factor: 7.640

View more
  2 in total

1.  Cell type specificity of female lung cancer associated with sulfur dioxide from air pollutants in Taiwan: an ecological study.

Authors:  Ching-Yu Tseng; Yi-Chia Huang; Shih-Yung Su; Jing-Yang Huang; Cheng-Hsiu Lai; Chia-Chi Lung; Chien-Chang Ho; Yung-Po Liaw
Journal:  BMC Public Health       Date:  2012-01-04       Impact factor: 3.295

2.  Histology-dependent prognostic role of pERK and p53 protein levels in early-stage non-small cell lung cancer.

Authors:  Sonia Molina-Pinelo; Luis Paz-Ares; Álvaro Quintanal-Villalonga; Mariló Mediano; Irene Ferrer; Ricardo Meléndez; Andrés Carranza-Carranza; Rocío Suárez; Amancio Carnero
Journal:  Oncotarget       Date:  2018-04-13
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.